Emphasizing Scalability Based on Combination with Anti-Resistance Cancer Drug

Presenting a Differentiated Approach with "OCT-648"

Oscotec announced on June 12 that it will participate in the "BIO USA 2026 (2026 BIO International Convention)" to be held at the San Diego Convention Center in California, USA, from June 22 to June 25 (local time).


Oscotec to Participate in BIO USA, Seeking Global Partnerships for Next-Generation Pipelines View original image

BIO USA 2026 is a leading global partnering event in the bio industry, attended annually by over 20,000 pharmaceutical and biotech companies, investors, and research institutions from more than 70 countries worldwide. At this event, Oscotec plans to seek opportunities to expand its global partnerships, focusing on its next-generation core pipelines: the anti-resistance cancer drug and the kidney fibrosis inhibitor development project (OCT-648).


Oscotec's anti-resistance cancer drug (ACART) is a pipeline with promising scalability, based on its potential for combination with existing treatments across various cancer types and targeted therapies. Its aim is to overcome the limitations of conventional cancer therapies by blocking key mechanisms by which cancer cells develop resistance to treatments and by suppressing recurrence. Oscotec currently possesses a diverse follow-up pipeline, including OCT-598, which is undergoing Phase 1 clinical trials, as well as ONC1, ONC2, and ONC3.


The kidney fibrosis inhibitor development project (OCT-648) has completed proof-of-concept (PoC) studies in animal models for its preclinical candidates, confirming consistent anti-fibrotic effects and a trend toward reduced fibrosis markers with increased dosage. Oscotec presents a differentiated approach by targeting the progression of fibrosis—a common pathological mechanism in kidney diseases—through indirect modulation of YAP/TAZ signaling, a key transcriptional regulatory pathway in renal fibrosis, via NUAK1 inhibition.


Building on the achievements of early global technology transfers for its core pipelines, Oscotec is pursuing growth into a more sustainable and scalable innovative biotech company. To this end, the company plans to strengthen its AI-based drug discovery capabilities, advance its proprietary platforms, establish integrated research data management systems, and advance R&D through global technology scouting and expanded open innovation initiatives.


Youngshin Kwak, Head of Research at Oscotec, stated, "With the recent technology transfer agreement for our autoimmune disease drug candidate, cevidoplenib, Oscotec has now accumulated a total of three global technology transfer achievements. This BIO USA convention will be a significant opportunity not only for networking but also to introduce Oscotec's follow-up pipelines and R&D capabilities to the global market and explore new opportunities for collaboration."



Meanwhile, on June 1, Oscotec signed a technology transfer agreement with Agios Pharmaceuticals, a global biopharmaceutical company specializing in rare disease treatments in the United States, for its autoimmune disease drug candidate, cevidoplenib. Under this agreement, Oscotec transferred exclusive clinical development and global commercialization rights related to cevidoplenib to Agios, securing potential revenue of up to USD 665 million (approximately KRW 1 trillion), including upfront payment and milestone payments for development, approval, and commercialization stages.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing